

## Arixtra® (fondaparinux) - New indication

- On December 23, 2024, the FDA approved Mylan's <u>Arixtra (fondaparinux)</u>, for the treatment of venous thromboembolism (VTE) in <u>pediatric patients aged 1 year or older weighing at least</u> 10 kg.
- Arixtra is also approved in adults for prophylaxis of deep vein thrombosis (DVT), treatment of acute DVT, and treatment of acute pulmonary embolism.
- The approval of Arixtra for the new indication was based on an open-label, single-arm retrospective clinical study in 366 pediatric patients aged 0.3 years to 17 years with VTE. The efficacy of Arixtra was based on measuring the proportion of patients with complete clot resolution up to 3 months (± 15 days).
  - Among the 325 pediatric patients in the efficacy analysis set, 44.9% (95% CI: 39.6, 50.4) experienced complete resolution of at least one clot, while 44% (95% CI: 38.7, 49.4) had complete resolution of all clots.
- Arixtra carries a boxed warning for spinal/epidural hematomas.
- The recommended initial dose of Arixtra for pediatric patients is 0.1 mg/kg subcutaneously once daily.
  - Refer to the <u>Arixtra drug label</u> for complete dosing and administration recommendations for pediatric and adult patients.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.